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emergency room visits, and quality-adjusted life-years.RESULTS: PP-LAI was dom-
inant. It cost €10,169/patient; outcomes included 330.1 days in remission, 25% were
hospitalized, 12% visited emergency rooms and 0.845 QALY. OLZ-LAI costs were
€11,589; patients experienced 326.8 remission days and 0.844 QALY; 27% were hos-
pitalized and 14% visited emergency rooms. RIS-LAI costs were €12,091; patients
experienced 323.8 remission days and 0.836 QALY; 30% were hospitalized and 14%
visited emergency rooms. For all products, costs were approximately 35% due to
drugs, 48% hospitalization, and the remainder due to medical care. The analysis
was robust against most variations in input values; adherence rates were sensitive.
PP-LAI was dominant over OLZ-LAI and RIS-LAI in 50% and 73% of simulations,
respectively. CONCLUSIONS: In Finland, PP-LAI dominated the other LAIs as it was
associated with a lower cost and better clinical outcomes.
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OBJECTIVES: To perform economic evaluation of paliperidone palmitate suspen-
sion for injection (PPI) compared to risperidone long acting injection (RLAI) for the
treatment of schizophrenia from Russian health care system point of view.
METHODS: Direct medical costs of treating schizophrenia with PPI and RLAI for 1
year were calculated in an Excel model. The model was based on simulation of rate
of relapse taking into account the expected adherence to treatment. The key pa-
rameters of the model were derived from the systematic review of the RCTs results,
e-STAR observational study (local data for Russia) and expert panel opinions. Ad-
herence simulation was based on the assumption that reduced number of injec-
tions will decrease number of patients giving up treatment and thus decrease
probability of relapse. Direct costs of treatment included hospitalization for the
relapse, outpatient care visits, and the cost of RLAI and PPI Sensitivity analysis to
the variations of key parameters was made. RESULTS: Analysis of the results of
RCTs has not shown superiority of RLAI-based treatment efficacy or safety over
PPI-based treatment. The only possible advantage is increased adherence rate due
to reduced number of injections per month. If adherence increases from 75.7% to
82.3% the costs of medical care in a hypothetical cohort of patients with schizo-
phrenia is less for PPI 6.36 bln USD vs 6.45 bln USD in case of RLAI (per year). Thus
difference in costs in a hypothetical cohort of patients with schizophrenia is 87,881
USD, or 87.88 USD per patient. Variation in the level of non-adherence to treatment
did not influence the results but the economic advantage of PPI disappears when its
price increases by1.5% from baseline. CONCLUSIONS: PPI may constitute a cost-
saving treatment option for patients with schizophrenia if its price is no more than
6.62 USD per mg.
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OBJECTIVES: To assess the cost-effectiveness of escitalopram as first line treat-
ment of MDD in Belgium. METHODS: The model structure was based on a decision
tree developed by the Swedish Dental and Pharmaceutical Benefits Agency (TLV).
Comparators included citalopram, fluoxetine, paroxetine, sertraline, duloxetine,
venlafaxine and mirtazapine. In the model, patients not achieving remission or
relapsing on the assessed treatment moved to a second therapeutic step (titration,
switch, add-on or transfer to a specialist). In case of failure in the second step or
following a suicide attempt, patients were assumed to be referred to secondary
care. The time horizon was one year and the analysis was conducted from the
NIHDI (national health insurance) and societal perspectives. Remission rates were
obtained from a network meta-analysis published by the TLV and other model
parameters were derived from the published literature and experts’ opinion. To
reflect local practices, a recent Belgian survey of 97 GPs (general practitioners) on
the management of MDD was used. The effect of uncertainty in model parameters
was estimated through scenario analyses and a probabilistic sensitivity analysis
(PSA). RESULTS: In the base case analysis, escitalopram was identified as the opti-
mal strategy: it dominated all other treatments except venlafaxine from the NIHDI
perspective, against which it was cost-effective with an incremental cost-effective-
ness ratio of €6,351 per quality-adjusted-life-year (QALY). Due to the high cost of
absenteeism, escitalopram dominated all other strategies from the societal per-
spective. At a threshold of €30,000 per QALYs from the NIHDI perspective, the PSA
showed that, in comparison to the other drugs, escitalopram had a probability
between 61% (vs. venlafaxine) and 100% (vs fluoxetine) to be identified as the op-
timal strategy. CONCLUSIONS: Escitalopram was identified as the optimal strategy
from the NIHDI and societal perspectives. This study investigated ways to present
sensitivity analyses while comparing multiple strategies.
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OBJECTIVES: To estimate cost-effectiveness of different (7 drugs) peroral atypi-
cal antipsychotics (AAP) vs haloperidol (H) for the treatment of schizophrenia.
METHODS: Cost-effectiveness analysis of AAP compared to H for schizophrenia
treatment was performed. A mathematical model based on simulation of treat-
ment outcomes in hypothetical cohort of patients was developed. Key parame-
ters of the model were determined using systematic review of the RCTs results
(improvement in clinical and functional status as measured by the PANSS and
CGI, frequency of relapse, adverse events), e-STAR observational study (local
data for Russia), epidemiological data and expert panel opinions. For each op-
tion direct costs of treatment were considered: hospitalization and outpatient
care, and the cost of medications for AAP- and H-based treatment. ICER (cost of
a day without exacerbation of the disease) for each AAP was calculated vs H.
RESULTS: According to published trials the treatment of schizophrenia in the
AAP-based therapy was associated with a significant improvement in PANSS
and CGI, decreased rate of relapse and adverse events compared to H-based
treatment. Analysis of the results of RCTs has not shown superiority of any
certain drug inside the AAP group. In case of application of AAP-based therapy
hospitalization rate decreases by 38% compared to H-based treatment but the
total cost of treatment remains lower for H. Depending on the drug ICERaap for
AAP vs H varies from 4,202 USD to 18,157 USD per day without exacerbation of
the disease. In group AAP paliperidone has the lowest ICER vs H - 4202 USD.
CONCLUSIONS: Results of the study suggest that AAP-are more efficacious com-
pared to H, the total cost of treatment remains lower for H. In-group AAP paliperi-
done is more cost-effective.
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OBJECTIVES: Depression has a lifetime prevalence of 10–25% among women and
5–12% among men. Selective serotonin reuptake inhibitors (SSRIs) are the most
used and the most cost effective treatment in long-term MDD. Since the introduc-
tion of generic SSRIs the costs of the branded drug have been questioned. The
objective of this study is to analyze the Cost-effectiveness of the most prescribed
SSRIs: sertraline, paroxetine, citalopram, that lost their patent, and escitalopram
that is still covered by a patent. METHODS: A decision analytic model was adapted
from TLV (Dental and Pharmaceutical Benefits Board, Sweden) in order to reflect
the current clinical practice in depression helped by a panel of Psychiatrists and
Health economists. Perspective used was the Lombardy Region Health Service and
the Time horizon was 12 months. Several scenario simulations, one way Sensitivity
analyses and Monte Carlo simulations have been performed in order to test the
robustness of the model. RESULTS: Base case scenario showed an ICER of escita-
lopram vs. sertraline of € 4.395. All the tests showed that citalopram and paroxetine
are dominated. One way Sensitivity analyses and tests were performed resulting in
ICER variation from € 135 to € 18.000, nevertheless Monte Carlo simulations have
shown an ICER stabilized at the mean value of around 4.000 euro confirming the
base case scenario. CONCLUSIONS: ICER represents the additional cost due to a
new technology related to its additional benefits. ICER has to be compared with a
meaningful threshold value under which a technology may be considered cost-
effective. Many agencies have studied this threshold. PBAC (Australia) propose €
25K, NICE (UK) propose € 35K. Comparing our base case scenario and also the ICER
ranges that came from the Sensitivity analyses (One way and multivariate) with
these thresholds escitalopram should be accepted as a cost-effective treatment for
MDD.
PMH28
USING COST-EFFECTIVENESS ANALYSIS TO DEFINE THE OPTIMAL GROUP OF
PATIENTS TO BENEFIT FROM RISPERIDONE LONG-ACTING INJECTABLE
Valencia-Mendoza A, Hernández-Garduño A
Janssen de Mexico, Mexico, D.F., Mexico
OBJECTIVES: Several studies have demonstrated that Risperidone Long-Acting
Injectable (RLAI) reduces psychotic relapses, hospitalization and resources used
among schizophrenic patients with poor adherence to oral medication. How-
ever, the magnitude of such reductions depends upon the baseline relapse rate.
This study is aimed at identifying the thresholds of relapse risk at which RLAI is
cost-effective, compared to Oral Olanzapine (OO), Oral Quetiapine (OQ) and
Haloperidol Decanoate (HD). METHODS: A Markov model was developed to sim-
ulate the natural history of schizophrenia for patients who have poor adherence
and high risk of relapse with oral medication. The strategies compared were
starting treatment with RLAI, OO, OQ or HD. Relapse probabilities, adherence
levels, side effects and treatment switching were derived from long-term obser-
vational data. Resource use and costs were obtained from Mexican public insti-
tutions. Patients transit through different health states in the model on a
monthly basis over a 10-year time horizon. Incremental cost and effectiveness
outcomes were discounted at 3% annually. RESULTS: In patients with Baseline
Annual Relapse Rate (BARR) equal or greater than 72.5%, RLAI is the most effec-
tive and less costly treatment (cost-saving) if effectiveness is measured in terms
of QALYs or relapses averted. In this case, RLAI produces 0.27 (5.13-5.4) addi-
tional discounted QALYs and avoids 3.97 relapses, compared to OO. According
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